<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03451019</url>
  </required_header>
  <id_info>
    <org_study_id>S-L2018</org_study_id>
    <nct_id>NCT03451019</nct_id>
  </id_info>
  <brief_title>Different Effects of Non-calcium Phosphate Binders on Serum Calcium</brief_title>
  <official_title>Effect of Lanthanum Carbonate and Sevelamer Hydrochloride on Gastrointestinal Calcium Absorption in Patients With Moderate to Advanced Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical Universtity of Lodz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical Universtity of Lodz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sevelamer hydrochloride (SE) can increase intestinal calcium absorption in contrast to
      lanthanum carbonate (LA). Study compared effect of LA and SE on serum and urine phosphate and
      calcium, and hormones regulating mineral-bone metabolism.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recent experimental studies have shown that a non-calcium based phosphate binder sevelamer
      hydrochloride can increase intestinal calcium absorption in contrast to lanthanum carbonate.
      It is unknown whether such the difference may have an effect on bone metabolism and/or modify
      the development of vascular calcification in patients with chronic kidney disease. The aim of
      the study was to compare the effect of a single dose of 1000 mg of lanthanum carbonate with
      2,4 mg of sevelamer hydrochloride on serum and urine calcium following an oral load of 5 g of
      calcium carbonate given with a meal with standardized phosphate content.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2011</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">July 15, 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Prospective randomized open-label study included 34 patients with CKD. Single oral dose of one of phosphate binders (sevelamer or lanthanum) were administered in random order 15 minutes after 5 g calcium carbonate with standardized meal. Serum calcium, phosphate and parathormone were measured at 0, 3, 6, 12, 24 hours after each medication. Bone alkaline phosphatase (BAP), sclerostin, calcitriol and FGF-23 were measured at 0, 12 and 24 hours after dose. Calcium and phosphate were measured in 24h urine collections after each drug.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the change of serum calcium for 24 hours after each drug</measure>
    <time_frame>3, 6, 12 and 24 hours after administration of each drug</time_frame>
    <description>absolute change vs baseline and 24h area under the curve</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>sevelamer hydrochloride</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>the subject receive a single dose of 2,4 g</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lanthanum carbonate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>the subject receive a single dose of 1.0 g</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevelamer Hydrochloride</intervention_name>
    <description>Single oral doses of lanthanum (1000 mg) or Sevelamer (2400 mg) were administered in random order 15 minutes after 5 g calcium carbonate with standardized meal</description>
    <arm_group_label>sevelamer hydrochloride</arm_group_label>
    <arm_group_label>lanthanum carbonate</arm_group_label>
    <other_name>Renagel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lanthanum Carbonate</intervention_name>
    <description>Single oral doses of lanthanum (1000 mg)</description>
    <arm_group_label>sevelamer hydrochloride</arm_group_label>
    <arm_group_label>lanthanum carbonate</arm_group_label>
    <other_name>Fosrenol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adult patient

          -  with eGFR ≤45 ml/min

        Exclusion Criteria:

          -  hypercalcemia (&gt;ULN),

          -  serum phosphate &gt;1.2 times normal value

          -  calcium-phosphate disturbances not associated with CKD, e.g. Paget disease,
             osteoporosis, any bone fracture within 6 months before study, multiple myeloma or any
             neoplastic disease, liver or biliary tract disease, primary hyperparathyroidism
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michal Nowicki, Prof.MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Lodz</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Nephrology, Hypertension and Kidney Transplantation</name>
      <address>
        <city>Łódź</city>
        <zip>90-153</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2018</study_first_submitted>
  <study_first_submitted_qc>February 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2018</study_first_posted>
  <last_update_submitted>February 23, 2018</last_update_submitted>
  <last_update_submitted_qc>February 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical Universtity of Lodz</investigator_affiliation>
    <investigator_full_name>Michal Nowicki</investigator_full_name>
    <investigator_title>Prof</investigator_title>
  </responsible_party>
  <keyword>chronic kidney disease - mineral bone disorder, phosphate-binders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Sevelamer</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

